Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1955 1
1961 3
1964 1
1970 1
1972 1
1974 1
1975 1
1977 1
1980 1
1982 1
1987 1
1991 1
1992 1
1997 4
1999 1
2000 1
2001 1
2006 2
2007 2
2008 1
2009 1
2010 4
2011 2
2013 2
2014 6
2015 4
2016 6
2017 4
2018 5
2019 8
2020 6
2021 3
2022 5
2023 4
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

82 results

Results by year

Filters applied: . Clear all
Page 1
Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR.
Ghorashian S, Kramer AM, Onuoha S, Wright G, Bartram J, Richardson R, Albon SJ, Casanovas-Company J, Castro F, Popova B, Villanueva K, Yeung J, Vetharoy W, Guvenel A, Wawrzyniecka PA, Mekkaoui L, Cheung GW, Pinner D, Chu J, Lucchini G, Silva J, Ciocarlie O, Lazareva A, Inglott S, Gilmour KC, Ahsan G, Ferrari M, Manzoor S, Champion K, Brooks T, Lopes A, Hackshaw A, Farzaneh F, Chiesa R, Rao K, Bonney D, Samarasinghe S, Goulden N, Vora A, Veys P, Hough R, Wynn R, Pule MA, Amrolia PJ. Ghorashian S, et al. Among authors: lazareva a. Nat Med. 2019 Sep;25(9):1408-1414. doi: 10.1038/s41591-019-0549-5. Epub 2019 Sep 2. Nat Med. 2019. PMID: 31477906 Clinical Trial.
CD19/CD22 targeting with cotransduced CAR T cells to prevent antigen-negative relapse after CAR T-cell therapy for B-cell ALL.
Ghorashian S, Lucchini G, Richardson R, Nguyen K, Terris C, Guvenel A, Oporto-Espuelas M, Yeung J, Pinner D, Chu J, Williams L, Ko KY, Walding C, Watts K, Inglott S, Thomas R, Connor C, Adams S, Gravett E, Gilmour K, Lal A, Kunaseelan S, Popova B, Lopes A, Ngai Y, Hackshaw A, Kokalaki E, Carulla MB, Mullanfiroze K, Lazareva A, Pavasovic V, Rao A, Bartram J, Vora A, Chiesa R, Silva J, Rao K, Bonney D, Wynn R, Pule M, Hough R, Amrolia PJ. Ghorashian S, et al. Among authors: lazareva a. Blood. 2024 Jan 11;143(2):118-123. doi: 10.1182/blood.2023020621. Blood. 2024. PMID: 37647647
[Acinetobacter: microbiological, pathogenetic and resistant properties].
Chebotar IV, Lazareva AV, Masalov YK, Mikhailovich VM, Mayanskiy NA. Chebotar IV, et al. Among authors: lazareva av. Vestn Ross Akad Med Nauk. 2014;(9-10):39-50. doi: 10.15690/vramn.v69i9-10.1130. Vestn Ross Akad Med Nauk. 2014. PMID: 25816642 Review. Russian.
CD34+-selected stem cell boost can safely improve cytopenias following CAR T-cell therapy.
Mullanfiroze K, Lazareva A, Chu J, Williams L, Burridge S, Silva J, Chiesa R, Rao K, Lucchini G, Ghorashian S, O'Reilly M, Carpenter B, Grandage V, Hough R, Roddie C, Amrolia PJ. Mullanfiroze K, et al. Among authors: lazareva a. Blood Adv. 2022 Aug 23;6(16):4715-4718. doi: 10.1182/bloodadvances.2022007572. Blood Adv. 2022. PMID: 35790110 Free PMC article. No abstract available.
Emergence of a ST307 clone carrying a novel insertion element MITEKpn1 in the mgrB gene among carbapenem-resistant Klebsiella pneumoniae from Moscow, Russia.
Shamina OV, Kryzhanovskaya OA, Lazareva AV, Alyabieva NM, Polikarpova SV, Karaseva OV, Mayanskiy NA. Shamina OV, et al. Among authors: lazareva av. Int J Antimicrob Agents. 2020 Feb;55(2):105850. doi: 10.1016/j.ijantimicag.2019.11.007. Epub 2019 Nov 23. Int J Antimicrob Agents. 2020. PMID: 31770629
82 results